Phase III X-TOLE2 data support azetukalner filing in focal onset seizures
Xenon Pharmaceuticals reported positive Phase III X-TOLE2 results for azetukalner in focal onset seizures. The company plans an FDA new drug application in Q3 2026.
Major Depressive Disorder
DiseaseDisease Profile
Major depressive disorder is a mood disorder marked by persistent depressive symptoms and clinically significant functional impairment. It is among the most common mental disorders and contributes substantial disability burden.
- Category
- mood disorder
- Prevalence
- In 2021, about 21.0 million U.S. adults (8.3%) had at least one major depressive episode.
Related News
Compass Pathways' psilocybin data lifts psychedelic drug stocks
Compass Pathways reported positive late-stage COMP360 psilocybin data in treatment-resistant depression and plans FDA talks ahead of a filing between October and December. The update lifted shares across several psychedelics developers.
Studies point to new psychedelic-based depression treatments
New findings on psychedelic-based depression treatments included a UK DMT trial in 34 adults and a mouse study of modified psilocin compounds with fewer hallucinogenic-like effects.
DMT trial shows lasting depression benefit as broader psychedelic studies map shared brain changes
A 34-person trial found that a single 21.5mg intravenous dose of DMT with psychotherapy produced rapid antidepressant effects lasting three to six months. Separate brain-scan research across five psychedelics found a shared pattern of weaker within-network links and stronger communication between brain networks.
Alzamend Neuro Reports Distinct Brain Profile for AL001 in Phase II Trial
Alzamend Neuro reports pharmacodynamic data showing AL001 may have a distinct brain interaction profile compared to lithium carbonate, with potential tolerability advantages. The Phase II trial analysis suggests AL001 affects key brain metabolites differently while maintaining lithium's core mechanism of action. Further confirmatory studies are planned to validate these initial findings.
Psilocybin studies link treatment to lasting shifts in values and fear of death
Studies of psilocybin found lasting shifts in life values in healthy volunteers and reduced fear of death in therapeutic settings. Trials have also reported benefits in cancer patients.
Johnson & Johnson Reports Strong Q4 2025 Results, Faces Ongoing Talc Litigation Challenges
Johnson & Johnson reported strong Q4 2025 earnings with $2.46 adjusted EPS and $24.56 billion in sales, beating estimates. The company faces over 67,000 active talc lawsuits following recent trial losses while projecting 2026 sales of $100-101 billion and maintaining a robust pipeline with recent FDA approvals and breakthrough designations.
FDA Approves Milsaperidone for Bipolar I and Schizophrenia, Advances Psychedelic Therapies
The FDA approved milsaperidone for bipolar I disorder and schizophrenia, while COMP360 psilocybin met its primary endpoint in a second phase 3 trial for treatment-resistant depression. Phase 2a data showed intravenous DMT (SPL026) significantly reduced depressive symptoms in major depressive disorder patients.
Lupin Partners with Spektus Pharma to Launch DeslaFlex Antidepressant in Canada
Lupin has signed a license and supply agreement with Spektus Pharma to commercialize DeslaFlex, a novel antidepressant for Major Depressive Disorder, in Canada, strengthening its CNS portfolio.
Higher Bupropion Doses Increase Fall Risk in Older Adults With Depression
A secondary analysis of the OPTIMUM trial found that higher doses of bupropion and prior fall history significantly increase fall risk in older adults with treatment-resistant depression receiving antidepressant augmentation.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07596914 |
Multi-site Feasibility of an Integrated Treatment for the Biology and Experience of Depression: The MULTIBED Study |
NOT_YET_RECRUITING | NA |
| NCT07594483 |
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium |
NOT_YET_RECRUITING | NA |
| NCT07592689 |
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) |
RECRUITING | PHASE3 |
| NCT07572526 |
tDCS: Sleep to Mood in Depression (S2M-D) |
NOT_YET_RECRUITING | NA |
| NCT07555743 |
Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia |
NOT_YET_RECRUITING | PHASE4 |
| NCT07554755 |
TIS for NSSI in Adolescent Depression |
RECRUITING | NA |
| NCT07534475 |
Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT |
NOT_YET_RECRUITING | NA |
| NCT07528157 |
Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression |
NOT_YET_RECRUITING | NA |
| NCT07526454 |
Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder |
COMPLETED | NA |
| NCT07512284 |
Mindfulness Engaged Neurostimulation for Depression (MEND II) |
RECRUITING | PHASE2 |